BMY - Bristol-Myers Squibb Company
| Previous close | 48.61 |
| Open | 49.00 |
| Bid | 48.89 x 1200 |
| Ask | 48.81 x 3200 |
| Day's range | 48.74 - 49.55 |
| 52-week range | 44.30 - 63.69 |
| Volume | 991,736 |
| Avg. volume | 15,019,485 |
| Market cap | 80.576B |
| Beta (3Y monthly) | 0.79 |
| PE ratio (TTM) | 15.69 |
| EPS (TTM) | 3.14 |
| Earnings date | 25 Jul 2019 |
| Forward dividend & yield | 1.64 (3.43%) |
| Ex-dividend date | 2019-07-03 |
| 1y target est | 56.10 |
- MarketWatch•17 minutes ago
This would be the worst-case scenario for health stocks, according to UBS
Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.
- Motley Fool•41 minutes ago
What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?
Shareholders get an all-or-nothing $9 contingent value right (CVR) when the acquisition closes.
- Zacks•23 hours ago
The Zacks Analyst Blog Highlights: Broadcom, Amgen, NVIDIA, Bristol-Myers and Restaurant Brands
The Zacks Analyst Blog Highlights: Broadcom, Amgen, NVIDIA, Bristol-Myers and Restaurant Brands
- Zacks•yesterday
Big Drugmakers That May Tread the M&A Path After Pfizer
There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
- Zacks•yesterday
Bristol-Myers (BMY) Upgraded to Buy: What Does It Mean for the Stock?
Bristol-Myers (BMY) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks•yesterday
3 Reasons Why Growth Investors Shouldn't Overlook Bristol-Myers (BMY)
Bristol-Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.
- Business Wire•yesterday
Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
Bristol-Myers Squibb Company (BMY) and Catalent, Inc. (CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.
- Zacks•2 days ago
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $47.81, marking a -0.84% move from the previous day.
- Zacks•2 days ago
Top Analyst Reports for Broadcom, Amgen & NVIDIA
Top Analyst Reports for Broadcom, Amgen & NVIDIA
- Zacks•2 days ago
Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio
Pfizer (PFE) offers $48 per share to buy Array BioPharma and strengthen its cancer portfolio.
- Bloomberg•3 days ago
Pfizer Expands in Cancer With $10.6 Billion Deal for Array
(Bloomberg) -- Pfizer Inc. will buy Array BioPharma Inc. for $10.6 billion to gain its promising new medicines for cancer, which could end or limit the use of punishing chemotherapy for some patients.The agreed price of $48 in cash is 62% above Array’s close last Friday -- already a record high. The company’s shares have soared thanks to drugs that target a mutation that’s found across a wide variety of tumor types, and could be used in treating a broad set of cancers in patients who carry the mutation. Array’s drugs, Braftovi and Mektovi, are already approved in the U.S. for use in advanced melanoma.Pfizer said in a statement that it will get royalties from the uses of drugs that Array has licensed out to other companies. It will acquire a pipeline of drugs in development, as well as future revenue from Braftovi and Mektovi in some other malignancies, such as colon cancer.Array shares rose 58% in to $46.67 at 9:32 a.m. in New York. Pfizer was little changed.Cancer has become one of the hottest areas for deal activity between drug and biotechnology companies. Research efforts dating back decades have helped scientists understand how genetic mutations cause some cancers to grow, and other scientific advances have helped them learn how tumors evade the body’s defenses. That knowledge has created an array of targets for drugmakers to attack, leading to new tailored therapies often defined by a tumor cell’s specific biology rather than its location in the body.Unlike other biotech stocks, many of which have pulled back from recent 2018 highs, Array’s shares have been on a steady march upward. The stock was already at a record before the deal announcement, following Array’s news last month of positive clinical trial results using Braftovi and Mektovi with Eli Lilly & Co.’s Erbitux. That combination could be the first chemotherapy-free regimen for some patients who have advanced colon cancer.Array’s drug targets a mutation called BRAF, which can show up in some forms of melanoma, colorectal and thyroid cancers, among others. Other drugs on the market target that mutation as well. Roche Holding AG’s Zelboraf is projected to bring in $168.7 million this year, according to a survey of analysts compiled by Bloomberg. Novartis AG’s Tafinlar is used in combination with another drug Mekinist, and the combination is expected to bring in $1.24 billion this year, according to analysts.The deal could also boost other biotech stocks, especially companies with drugs in the later stages of development that could be appetizing for big drugmakers. “We expect this announcement to provide a tailwind for the sector,” said Stephen Willey, an analyst with Stifel Nicolaus & Co. He called the premium for the Array deal appropriate, given the company’s positive clinical trial news.The deal is Pfizer’s biggest since its 2016 acquisition of Medivation for $14 billion, another blockbuster cancer deal that the New York-based company used to expand its oncology offerings. With that takeover, Pfizer gained Xtandi, a prostate cancer drug that last year Xtandi brought it $699 million.“From an overall capital allocation perspective, our priorities don’t change,” Pfizer Chief Financial Officer Frank D’Amelio said on a conference call Monday. The company will continue to look at dividends, buybacks and small or mid-size deals, and doesn’t see the need for a large merger, he said. Pfizer has lagged behind drugmakers like Merck & Co. and Bristol-Myers Squibb Co. that have brought to market best-selling drugs that use the immune system to attack tumors. But the company has acquired or developed a set of other treatments for breast, prostate other cancers that target disease based on its biological profile. Such methods can result in more effective drugs, fewer side-effects, or both.Pfizer plans to fund the deal with a combination of debt and cash. It said it expects the deal to close in the second half of this year. The deal comes with a $400 million termination fee, according to a regulatory filing by Array.Guggenheim Securities and Morgan Stanley & Co. served as Pfizer’s financial advisers, and Wachtell, Lipton, Rosen & Katz gave legal advice. Centerview Partners was Array’s financial adviser, and Skadden, Arps, Slate, Meagher & Flom LLP served as its legal adviser.(Updates with analyst comment in seventh paragraph. An earlier version of this story corrected the description of Pfizer’s advisers in the final paragraph.)\--With assistance from Marthe Fourcade and Cynthia Koons.To contact the reporter on this story: Drew Armstrong in New York at darmstrong17@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Cécile DauratFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Motley Fool•4 days ago
Is It Too Late to Buy Celgene Stock?
The clock is ticking for Celgene's acquisition by Bristol-Myers Squibb. But is Celgene still a stock worth buying?
- Simply Wall St.•6 days ago
Should Bristol-Myers Squibb Company (NYSE:BMY) Be Part Of Your Dividend Portfolio?
Today we'll take a closer look at Bristol-Myers Squibb Company (NYSE:BMY) from a dividend investor's perspective...
- Zacks•6 days ago
3 Big Pharma Stocks to Buy Right Now
These big pharma stocks all have a Zacks Rank 2 or better.
- Zacks•6 days ago
Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.
- Business Wire•6 days ago
Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
In a descriptive analysis, addition of Empliciti to pomalidomide and dexamethasone reduced risk of death by 46% among patients with RRMM
- Zacks•7 days ago
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.
- Business Wire•7 days ago
Bristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty one cents per share on the $.10 par value Common Stock of the corporation.
- Business Wire•7 days ago
New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients
PRINCETON, N.J.--(BUSINESSWIRE)-- Findings from head-to-head Early AMPLE study are consistent with earlier studies, adding to body of research showing differences between mechanisms of biologic therapies ...
- MarketWatch•7 days ago
Price target on Bristol-Myers stock cut to $51 at UBS
Analysts at UBS cut their price target on shares of Bristol-Myers Squibb Co. on Thursday to $51 from $55 per share, citing lower-than-consensus expectations for the company's immuno-oncology franchise. The firm holds "cautious views" on an important trial evaluating a treatment targeting non-small cell lung cancer (NSCLC) tumors, analysts led by Navin Jacob wrote in a note to clients. The trial, called CheckMate-227, is looking at a combination of Bristol's drugs Opdivo and Yervoy -- or Opdivo alone -- as a treatment for NSCLC cases with high tumor mutational burden. In January, Bristol said it was pulling its marketing application for the drug after talks with the Food and Drug Administration convinced the company it needed more data. Shares of Bristol have fallen 8.4% in the year to date through Wednesday, while the S&P 500 has 14.9%.
